搡老女人多毛老妇女中国,日韩亚洲欧美中文高清在线,人妻少妇一区二区三区,色妞色综合久久夜夜,日本熟妇xxxx

Your Good Partner in Biology Research

  1. Home
  2. 抗體
  3. 重組抗體
  4. GAA Recombinant Monoclonal Antibody

GAA Recombinant Monoclonal Antibody

  • 中文名稱：
    GAA重組抗體
  • 貨號(hào)：
    CSB-RA566370A0HU
  • 規(guī)格：
    ￥1320
  • 圖片：
    • IHC image of CSB-RA566370A0HU diluted at 1:50 and staining in paraffin-embedded human placenta tissue performed on a Leica BondTM system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4°C overnight. The primary is detected by a Goat anti-rabbit polymer IgG labeled by HRP and visualized using 0.15% DAB.
    • IHC image of CSB-RA566370A0HU diluted at 1:50 and staining in paraffin-embedded human breast cancer performed on a Leica BondTM system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4°C overnight. The primary is detected by a Goat anti-rabbit polymer IgG labeled by HRP and visualized using 0.15% DAB.
  • 其他：

產(chǎn)品詳情

  • 產(chǎn)品描述：
    CSB-RA566370A0HU GAA重組單克隆抗體是針對(duì)酸性α-葡萄糖苷酶（GAA）靶點(diǎn)開發(fā)的高特異性科研工具，適用于酶聯(lián)免疫吸附（ELISA）和免疫組織化學(xué)（IHC）實(shí)驗(yàn)。該抗體識(shí)別的GAA蛋白是溶酶體糖原代謝的關(guān)鍵酶，其功能異常與糖原貯積病II型（龐貝?。┑冗z傳代謝疾病密切相關(guān)。經(jīng)實(shí)驗(yàn)驗(yàn)證，本產(chǎn)品在IHC應(yīng)用中展現(xiàn)優(yōu)異的組織抗原定位能力，推薦使用稀釋比例為1:50至1:200，可清晰檢測石蠟包埋樣本中GAA的細(xì)胞特異性表達(dá)分布。其在ELISA平臺(tái)的應(yīng)用則支持靶蛋白的定量分析需求，為研究人員提供可靠的檢測數(shù)據(jù)。該抗體適用于疾病模型構(gòu)建、代謝通路研究及治療性酶活性調(diào)控等基礎(chǔ)科研領(lǐng)域，特別在糖原代謝異常相關(guān)疾病的病理機(jī)制探索、基因治療靶點(diǎn)驗(yàn)證等方向具有應(yīng)用價(jià)值。通過嚴(yán)格的免疫原篩選和表位驗(yàn)證，確?？贵w與GAA蛋白的高度結(jié)合特異性，為體外實(shí)驗(yàn)提供精準(zhǔn)的檢測保障。
  • Uniprot No.：
  • 基因名：
  • 別名：
    Lysosomal alpha-glucosidase (EC 3.2.1.20) (Acid maltase) (Aglucosidase alfa) [Cleaved into: 76 kDa lysosomal alpha-glucosidase, 70 kDa lysosomal alpha-glucosidase], GAA
  • 反應(yīng)種屬：
    Human
  • 免疫原：
    A synthesized peptide derived from Human GAA
  • 免疫原種屬：
    Homo sapiens (Human)
  • 標(biāo)記方式：
    Non-conjugated
  • 克隆類型：
    Monoclonal
  • 抗體亞型：
    Rabbit IgG
  • 純化方式：
    Affinity-chromatography
  • 克隆號(hào)：
    5E5
  • 濃度：
    It differs from different batches. Please contact us to confirm it.
  • 保存緩沖液：
    Rabbit IgG in phosphate buffered saline, pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.
  • 產(chǎn)品提供形式：
    Liquid
  • 應(yīng)用范圍：
    ELISA, IHC
  • 推薦稀釋比：
    Application Recommended Dilution
    IHC 1:50-1:200
  • Protocols：
  • 儲(chǔ)存條件：
    Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
  • 貨期：
    Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
  • 用途：
    For Research Use Only. Not for use in diagnostic or therapeutic procedures.

產(chǎn)品評(píng)價(jià)

靶點(diǎn)詳情

  • 功能：
    Essential for the degradation of glycogen in lysosomes. Has highest activity on alpha-1,4-linked glycosidic linkages, but can also hydrolyze alpha-1,6-linked glucans.
  • 基因功能參考文獻(xiàn)：
    1. PI-rhGAA may have the potential to be a useful therapeutic option for improving the treatment of Pompe disease. PMID: 29102549
    2. The most common mutation was c.-32-13T, G. in Pompe disease. PMID: 29181627
    3. The narrow substrate-binding pocket of rhGAA is located near the C-terminal ends of beta-strands of the catalytic (beta/alpha)8 domain and shaped by a loop from the N-terminal beta-sheet domain and both inserts I and II. PMID: 29061980
    4. This is the first study of rhGAA to differentiate M6P glycans and identify their attachment sites, despite rhGAA already being an approved drug for Pompe disease. PMID: 29274340
    5. GAA mutation is associated with Pompe disease. PMID: 28763149
    6. Enzyme activities (acid alpha-glucosidase (GAA), galactocerebrosidase (GALC), glucocerebrosidase (GBA), alpha-galactosidase A (GLA), alpha-iduronidase (IDUA) and sphingomyeline phosphodiesterase-1 (SMPD-1)) were measured on ~43,000 de-identified dried blood spot (DBS) punches, and screen positive samples were submitted for DNA sequencing to obtain genotype confirmation of disease risk PMID: 27238910
    7. enzyme replacement therapy (ERT) (alglucosidase alfa) stabilizes respiratory function and improves mobility and muscle strength in late-onset Pompe disease.Lysosomal glycogen in muscle biopsies from treatment-naive LOPD patients was reduced post-ERT (alglucosidase alfa). PMID: 27473031
    8. In adults with Pompe disease, antibody formation does not interfere with rhGAA efficacy in the majority of patients, is associated with IARs, and may be attenuated by the IVS1/delex18 GAA genotype PMID: 27362911
    9. Reanalysis of the patient's DNA sample using next generation sequencing (NGS) of a panel of target genes causing glycogen storage disorders demonstrated compound heterozygosity for a point mutation and an exonic deletion in the GAA gene. PMID: 28657663
    10. Thirteen novel and two common GAA mutations were identified in this study. The allelic frequency of c.2662G > T (p.Glu888X) was 23.1% in northern Chinese patients and 4.2% in southern Chinese patients, whereas the allelic frequency of c.1935C >A (p.Asp645Glu) was 20.8% in southern and 3.8% in northern Chinese patients. PMID: 28394184
    11. This is the first report of the alpha-glucosidase inhibitory activity of compounds 20, 26, and 29, and the findings support the important role of Eremanthus species as novel sources of new drugs and/or herbal remedies for treatment of type 2 diabetes. PMID: 27322221
    12. Compared with controls, GAA gene expression levels in coronary artery disease (CAD) patients were significantly increased, suggesting that GAA may be involved in the CAD development. PMID: 26580301
    13. Study reports on the clinical, biochemical, morphological, muscle imaging, and genetic findings of six adult Pompe patients from five unrelated families with the c.-32-13T>G GAA gene mutation in homozygous state. All patients had decreased GAA activity and elevated creatine kinase levels. PMID: 26231297
    14. glycogen storage disease type II is caused by deficiency of GAA activity resulting from mutation of GAA gene PMID: 26575883
    15. RT-PCR followed by DNA sequence analysis of patients with Pompe disease revealed new variant in GAA gene resulting in aberrant splicing event. PMID: 25243733
    16. Findings indicate that GAA c.2238G > C (p.W746C) novel mutation is the most common mutation in mainland Chinese late-onset Pompe patients, as observed in Taiwanese patients expanding the genetic spectrum of the disease. PMID: 25526786
    17. this study shows several alterations distributed along the GAA gene in a sample of Brazilian families. PMID: 25681614
    18. Mutations in acid alpha-glucosidase gene is associated with Pompe disease. PMID: 25026126
    19. GAA deficiency results in reduced mTORC1 activation that is partly responsible for the skeletal muscle wasting phenotype and can be amerliorated by leucine supplementation. PMID: 25231351
    20. The phenotype LO-GSDII with GAA mutation in the North of Italy seems not significantly different from other LO-GSDII populations in Europe or the USA. PMID: 24158270
    21. Data shows the largest informative family with late-onset Pompe disease described in the literature showing a peculiar complex set of mutations of GAA gene that may partially elucidate the clinical heterogeneity of this family. PMID: 24107549
    22. 7 of 27 in: Gene. 2014 Mar 1;537(1) Novel GAA sequence variant c.1211 A>G reduces enzyme activity but not protein expression in infantile and adult onset Pompe disease. PMID: 24384324
    23. This study demonstrates that the c.-32-13T>G mutation of GAA gene abrogates the binding of the splicing factor U2AF65 to the polypyrimidine tract of exon 2 and that several splicing factors affect exon 2 inclusion. PMID: 24150945
    24. study describes two unrelated cases affected with classical early-onset Pompe disease, both pertaining to the same small Mexican region, with the same novel homozygous frameshift mutation at gene GAA (c.1987delC) PMID: 24399866
    25. Mutations in the GAA gene is associated with glycogen storage disease type II. PMID: 23884227
    26. Adult patients with alpha-glucosidase mutations other than c.-32-13 T>G can have very low alpha-glucosidase activity in fibroblasts but express higher activity in muscle and store less glycogen in muscle than patients with infantile Pompe disease. PMID: 23000108
    27. Study gave an update of the pompe disease mutation database with 60 novel GAA sequence variants and additional studies on the functional effect of 34 previously reported variants. PMID: 22644586
    28. Transcriptional response to GAA deficiency (Pompe disease) in infantile-onset patients PMID: 22658377
    29. Report genetic testing to indentify GAA mutations in German patients with late-onset glycogen storage disease type II. PMID: 18607768
    30. we define a critical role for endoplasmic reticulum stress in the activation of autophagy due to the 546G>T acid alpha glucosidase mutation PMID: 21982629
    31. No common mutation is found in association with low levels of acid alpha-glucosidase activity in late-onset Pompe disease; most patients produce unprocessed forms of GAA protein compared with patients who have higher GAA activity. PMID: 21484825
    32. Mutation analysis of the GAA gene revealed the p.D645E in all patients with Pompe disease, suggesting it as the most common mutation in the Thai population. PMID: 21039225
    33. The enzymatic screening of Pompe disease can be justified in patients with myopathies of unknown etiology in this report of a Mexican patient with late-onset glycogen-storage disease type 2. PMID: 20350966
    34. Data show that p.R1147G missense mutation impaired glucosidase activity. PMID: 19834502
    35. Homozygosity for multiple contiguous single-nucleotide polymorphisms as an indicator of large heterozygous deletions: identification of a novel heterozygous 8-kb intragenic deletion (IVS7-19 to IVS15-17) in a patient with glycogen storage disease type II PMID: 11854868
    36. novel target of the Notch-1/Hes-1 signaling pathway PMID: 12065598
    37. 2 novel mutations of the acid alpha-glucosidase gene, P361L and R437C, were found in a juvenile-onset glycogen storage disease type II (GSDII) 16-year-old Chinese patient. The asymptomatic 13-year-old brother of the proband is also compound heterozygote PMID: 12601120
    38. mutations in the alpha glucosidase gene is associated with infantile onset glycogen storage disease type II. PMID: 12923862
    39. Childhood Pompe disease demonstrating phenotypic variability of p.Asp645Asn. PMID: 15145338
    40. data show that the mature forms of GAA characterized by polypeptides of 76 or 70 kDa are in fact larger molecular mass multicomponent enzyme complexes; peptides released during proteolytic processing remained tightly associated with the major species PMID: 15520017
    41. 2 novel mutations (Ala237Val and Gly293Arg) were foundin the acid alpha-glucosidase gene in a Pompe disease patient with vascular involvement. PMID: 15668445
    42. Acid-alpha-glucosidase activity and specific activity, and lysosomal glycogen content are useful predictors of age of onset in Pompe disease PMID: 15993875
    43. Complete molecular analysis of the GAA gene of patients with late onset glycogen storage disease type II shows missense mutations and splicing mutations. PMID: 16917947
    44. From 14 Argentinean patients diagnosed with either infantile or late-onset disease, we identified 14 distinct mutations in the acid alpha-glucosidase (GAA) gene including nine novel variants. PMID: 17056254
    45. Two new missense mutations (p.266Pro>Ser and p.439Met>Lys) were new missense mutations causing late onset GSD II. PMID: 17092519
    46. Patients with the same c.-32-13T-->G haplotype (c.q. GAA genotype) may manifest first symptoms at different ages, indicating that secondary factors may substantially influence the clinical course of patients with this mutation. PMID: 17210890
    47. demonstrated a significant increase of GAA activity (1.3-7.5-fold) after imino sugar treatment in fibroblasts from patients carrying the mutations L552P (three patients) and G549R (one patient) PMID: 17213836
    48. N-glycans of recombinant human GAA were expressed in the milk of transgenic rabbits. PMID: 17293352
    49. The role of autophagy in Pompe disease was examined by analyzing single muscle fibers. PMID: 17592248
    50. Mutations in glucosidase alpha is asspciated with glycogen storage disease type II PMID: 17616415

    顯示更多

    收起更多

  • 相關(guān)疾?。?/div>
    Glycogen storage disease 2 (GSD2)
  • 亞細(xì)胞定位：
    Lysosome. Lysosome membrane.
  • 蛋白家族：
    Glycosyl hydrolase 31 family
  • 數(shù)據(jù)庫鏈接：

    HGNC: 4065

    OMIM: 232300

    KEGG: hsa:2548

    STRING: 9606.ENSP00000305692

    UniGene: Hs.1437